Globally, the number of 3D printing patent applications for the pharmaceutical industry declined by 0.3% in Q3 2022 when compared to the preceding quarter. The total number of 3D printing-related grants dropped by 7% in Q3 2022, according to GlobalData’s Patent Analytics.
Notably, 336 3D-printing-related patent applications were filed in the pharmaceutical sector in Q3 2022 compared to 337 in prior quarter.
15% of patenting activity came from the top five largest companies
Arkema was the company that filed the most 3D printing patents in the sector of pharmaceutical operations and technologies in Q3 2022. This quarter, Arkema filed 23 3D printing patents, compared to 18 the previous quarter. It was followed by Johnson & Johnson with 10 3D printing patent filings, Jabil (7 filings), and 3D Systems (6 filings) in Q3 2022.
The US was the main driver of patenting activity with 26% of total patent filings
In Q3 2022, the US accounted for 26% of 3D printing-related patent filings. China (20%) followed by South Korea (10%). The US accounted for 1% less than the 27% it held in Q2 2022.